IP Library › Granted Patent US 12,441,816
Granted Patent B2
US 12,441,816 · App. 17/933,954 · Granted Oct 14, 2025

Heterodimeric Fc for making fusion proteins and bispecific antibodies

Inventors: Zhi Liu (Shoreline, WA); Victor Hermand (Lynnwood, WA); Hua Liu (Shoreline, WA); Wei Yan (Sammamish, WA)
Assignee: QILU PUGET SOUND BIOTHERAPEUTICS CORPORATION
C07K16/462C07K16/2887C07K16/2896C12N15/86C07K2317/24C07K2317/31C07K2317/53C07K2317/565C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,441,816
App. No.
17/933,954
Granted
Oct 14, 2025
Kind
B2
Abstract

Provide herein are variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies optionally produced by a host cell line, nucleic acids encoding the variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies, host cells containing such nucleic acids, and methods of treatment using the variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies, or nucleic acids encoding the variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies described herein. Also described are methods of producing the variant-Fc-region fusion proteins, variant-Fc-region-antibodies and/or heterodimeric-variant-Fc-region-bispecific-antibodies in host cells.

Claims (57)

1. A variant-Fc-region comprising a set of amino acid substitutions compared to native human IgG1, IgG2, or IgG4, selected from: a first variant-Fc-region comprising S364D, K370D, N390D, K392G and S400D; or a second variant-Fc-region comprising S364K, N390P and S400K, according to EU numbering.

2. The variant-Fc-region of claim 1 , further comprising Y349C in the first variant-Fc-region and S354C in the second variant-Fc-region.

3. The variant-Fc-region of claim 1 , wherein said variant-Fc-region is a variant-Fc-region-fusion protein further comprising a partner-ligand recombinantly fused thereto at either the N-terminus or C-terminus.

4. The variant-Fc-region fusion protein of claim 3 , wherein the partner-ligand is selected from the group consisting of: extracellular domains of receptors, soluble full-length or domain of cytokines, ligands, enzymes, antibody domains, peptides, anti-CD3 scFv, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-11, IL-12, IL-13, and IL-18, granulocyte CSF (G-CSF), granulocyte-macrophage CSF (GM-CSF), monocyte macrophage CSF (M-CSF), tumor necrosis factor (TNF) alpha and beta, and interferon-α, β, or γ, or mutein cytokines.

5. A substantially pure heterodimeric-variant-Fc-region fusion protein composition, wherein said composition comprises the first and second variant-Fc-region of claim 1 .

6. The substantially pure heterodimeric-variant-Fc-region fusion composition of claim 5 , wherein the composition is substantially free of homodimeric proteins, and wherein the amount of homodimeric proteins in said composition is less than 5, 4, 3, 2, 1, 0.5, 0.4, 0.3, 0.2, or 0.1%.

7. The substantially pure heterodimeric-variant-Fc-region fusion composition of claim 6 , wherein the amount of homodimeric proteins in said composition is less than 2%.

8. The substantially pure heterodimeric-variant-Fc-region fusion composition of claim 6 , wherein the amount of homodimeric proteins in said composition is less than 1%.

9. The substantially pure heterodimeric-variant-Fc-region fusion composition of claim 6 , wherein the amount of homodimeric proteins in said composition is less than 0.5%.

10. The substantially pure heterodimeric-variant-Fc-region fusion composition of claim 6 , wherein the amount of homodimeric proteins in said composition is less than 0.4%.

11. The substantially pure heterodimeric-variant-Fc-region fusion composition of claim 6 , wherein the amount of homodimeric proteins in said composition is less than 0.3%.

12. The substantially pure heterodimeric-variant-Fc-region fusion composition of claim 6 , wherein the amount of homodimeric proteins in said composition is less than 0.2%.

13. The substantially pure heterodimeric-variant-Fc-region fusion composition of claim 6 , wherein the amount of homodimeric proteins in said composition is less than 0.1%.

14. The substantially pure heterodimeric-variant-Fc-region fusion protein composition of claim 5 , wherein:

a. only one of the first and second variant-Fc-regions comprises a partner-ligand attached thereto at either the N-terminus or C-terminus;

b. both the first and second variant-Fc-regions comprise the same partner-ligands attached thereto at either the N-terminus or C-terminus; or

C. both the first and second variant-Fc-regions comprise different partner-ligands attached thereto at either the N-terminus or C-terminus.

15. The substantially pure heterodimeric-variant-Fc-region fusion protein composition of claim 14 , wherein the partner-ligand is selected from the group consisting of: extracellular domains of receptors, soluble full-length or domain of cytokines, ligands, enzymes, antibody domains, peptides, anti-CD3 scFv, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-11, IL-12, IL-13, and IL-18, granulocyte CSF (G-CSF), granulocyte-macrophage CSF (GM-CSF), monocyte macrophage CSF (M-CSF), tumor necrosis factor (TNF) alpha and beta, and interferon-α, β, or γ, or mutein cytokines.

16. The substantially pure heterodimeric-variant-Fc-region protein composition of claim 5 , wherein said composition is selected from a heterodimeric variant-Fc-region monospecific; or a heterodimeric variant-Fc-region bispecific antibody.

17. A heterodimeric variant-Fc-region-bispecific antibody comprising the first and second variant-Fc region of claim 1 , said heterodimeric variant-bispecific antibody further comprising:

a. a first and second Heavy Chain (HC) region, wherein the first and second HC regions differ from each other; and

b. a first and second Light Chain (LC) region, wherein the first and second LC regions differ from each other.

18. The heterodimeric bispecific antibody of claim 17 , wherein the first HC region comprises substitutions K147D, F170C, V173C in its CH1 domain and C220G in upper hinge region of the HC region; the first LC region comprises substitutions S131K, Q160C, S162C and C214S in its Cκ domain; and the first HC and first LC form a cognate pair, whereas no substitution is introduced in the second HC and the second LC.

19. The heterodimeric bispecific antibody of claim 17 , wherein no substitution is introduced in the first HC and the first LC, whereas the second HC region comprises substitutions K147D, F170C, V173C in its CH1 domain and C220G in upper hinge region of the HC region; the second LC region comprises substitutions S131K, Q160C, S162C and C214S in its Cκ domain.

20. The heterodimeric bispecific antibody of claim 17 , wherein the heterodimeric bispecific antibody is selected from:

a. anti-hCD20×hCD37 comprising an anti-hCD20 VL CDR1, VL CDR2, VL CDR3 set forth in SEQ ID NO:36, or a complete anti-CD20 VL sequence set forth in SEQ ID NO:36; an anti-hCD20 VH CDR1, VH CDR2, and VH CDR3 set forth in SEQ ID NO:30, or a complete anti-CD20 VH sequence set forth in SEQ ID NO:30; an anti-hCD37 VL CDR1, VL CDR2, VL CDR3 set forth in SEQ ID NO:50, or a complete anti-CD37 VL sequence set forth in SEQ ID NO:50; and an anti-hCD37 VH CDR1, VH CDR2, and VH CDR3 set forth in SEQ ID NO:42, or a complete anti-hCD37 VH sequence set forth in SEQ ID NO:42; and

b. anti-hSIRPα×hCLDN18.2 comprising an anti-hSIRPα VL CDR1, VL CDR2, VL CDR3 set forth in SEQ ID NO:74, or a complete anti-hSIRPα VL sequence set forth in SEQ ID NO: 74; an anti-hSIRPα VH CDR1, VH CDR2, and VH CDR3 set forth in SEQ ID NO:70, or a complete anti-hSIRPα VH sequence set forth in SEQ ID NO:70; an anti-hCLDN18.2 VL CDR1, VL CDR2, VL CDR3 set forth in SEQ ID NO:64, or a complete anti-hCLDN18.2 VL sequence set forth in SEQ ID NO:64; and an anti-hCLDN18.2 VH CDR1, VH CDR2, and VH CDR3 set forth in SEQ ID NO:58, or a complete anti-hCLDN18.2 VH sequence set forth in SEQ ID NO:58.

21. The heterodimeric bispecific antibody of claim 17 , corresponding to an anti-hCD20×hCD37, selected from the group consisting of:

a. the first HC region corresponding to anti-hCD37 Ab1.A1.2 HC (SEQ ID NO:42); the first LC region corresponding to anti-hCD37 Ab1.A1.1 LC (SEQ ID NO: 50); the second HC region corresponding to anti-hCD20 Ab1.2.5 HC (SEQ ID NO: 30); and the second LC region corresponding to anti-hCD20 Ab1.2 (SEQ ID NO: 36); and

b. the first HC region corresponding to anti-hCD37 Ab1.A1.3 HC (SEQ ID NO:44); the first LC region corresponding to anti-hCD37 Ab1.A1.ILC (SEQ ID NO: 50); the second HC region corresponding to anti-hCD20 Ab1.2.6 HC (SEQ ID NO: 32); and the second LC region corresponding to anti-hCD20 Ab1.2 (SEQ ID NO: 36).

22. The heterodimeric bispecific antibody of claim 17 , corresponding to an anti-hSIRPα×hCLDN18.2, selected from the group consisting of:

a. the first HC region corresponding to anti-hCLDN18.2 HC1 (SEQ ID NO:58); the first LC region corresponding to anti-hCLDN18.2 LC1 (SEQ ID NO: 64); the second HC region corresponding to anti-hSIRPα HC2 (SEQ ID NO:70); and the second LC region corresponding to anti-hSIRPα LC2 (SEQ ID NO:74).

23. A host cell line that produces the variant-Fc-region, variant-Fc-region fusion protein or heterodimeric-variant-Fc-region antibody of claim 1 .

24. The host cell line of claim 23 , which is a mammalian cell line.

25. The host cell line of claim 24 , which is a CHO cell line.

26. One or more nucleic acid(s) encoding the variant-Fc-region, variant-Fc-region fusion protein or heterodimeric-variant-Fc-region antibody of claim 1 .

27. One or more vector(s) containing the nucleic acid(s) of claim 26 .

28. The vector(s) of claim 27 , each of which is a mammalian expression vector.

29. The vector(s) of claim 27 , each of which is a viral vector.

30. The vector(s) of claim 29 , each of which is an adenovirus, an adeno-associated virus (AAV), a retrovirus, a vaccinia virus, a modified vaccinia virus Ankara (MVA), a herpes virus, a lentivirus, or a poxvirus vector.

31. A host cell line containing the nucleic acid(s) and/or the vector(s) of claim 26 .

32. A substantially pure heterodimeric-variant-Fc-region antibody composition, comprising a set of amino acid substitutions compared to native human IgG1, IgG2, or IgG4, wherein said composition comprises:

a heterodimeric-variant-Fc-region antibody comprising a first variant Fc-region having 4 variant negative charge residues at specified residues on the CH3 region; and comprising a second variant Fc-region having 2 variant and 2 native positive charge residues at the corresponding-specified residues on the CH3 region as in the first Fc-region, wherein an amount of homodimeric antibodies in said composition is less than 5, 4, 3, 2, 1, 0.5, 0.4, 0.3, 0.2, or 0.1%, wherein the first variant Fc-region comprises K392G and has 4 variant negative charge residues comprising S364D, K370D, N390D, and S400D, according to EU numbering.

33. The composition of claim 32 , wherein the second variant Fc-region comprises N390P and has 2 variants and 2 native positive charge residues comprising S364K, 370K, 392K, and S400K.

34. The composition of claim 10 , further comprising a variant cysteine residue in the CH3 region of the first and second variant Fc-regions.

35. The composition of claim 34 , wherein the variant cysteine residue in the CH3 region of the first variant Fc-region corresponds to Y349C.

36. The composition of claim 34 , wherein the variant cysteine residue in the CH3 region of the second variant Fc-region corresponds to S354C.

37. The substantially pure heterodimeric-variant-Fc-region antibody composition of claim 32 , wherein the amount of homodimeric proteins in said composition is less than 2%.

38. The substantially pure heterodimeric-variant-Fc-region antibody composition of claim 32 , wherein the amount of homodimeric proteins in said composition is less than 1%.

39. The substantially heterodimeric-variant-Fc-region antibody composition of claim 32 , wherein the amount of homodimeric proteins in said composition is less than 0.5%.

40. The substantially pure heterodimeric-variant-Fc-region antibody composition of claim 32 , wherein the amount of homodimeric proteins in said composition is less than 0.4%.

41. The substantially pure heterodimeric-variant-Fc-region antibody composition of claim 32 , wherein the amount of homodimeric proteins in said composition is less than 0.3%.

42. The substantially pure heterodimeric-variant-Fc-region antibody composition of claim 32 , wherein the amount of homodimeric proteins in said composition is less than 0.2%.

43. The substantially pure heterodimeric-variant-Fc-region antibody composition of claim 32 , wherein the amount of homodimeric proteins in said composition is less than 0.1%.

44. A humanized anti-hCLDN18.2 monoclonal antibody, wherein said antibody comprises a variable heavy chain (VH) amino acid sequence corresponding to SEQ ID NO:52; and a variable light chain (VL) amino acid sequence corresponding to SEQ ID NO: 60.

45. The humanized anti-hCLDN18.2 monoclonal antibody of claim 44 , further comprising a heavy chain (HC) amino acid sequence selected from SEQ ID NO:54, SEQ ID NO: 56 or SEQ ID NO:58; and a light chain (LC) amino acid sequence corresponding to SEQ ID NO:64.

46. The humanized anti-hCLDN18.2 monoclonal antibody of claim 45 , wherein said antibody comprises a heavy chain (HC) amino acid sequence corresponding to SEQ ID NO:58.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2023
From: LIU, ZHI; HERMAND, VICTOR; LIU, HUA; YAN, WEI
To: QILU PUGET SOUND BIOTHERAPEUTICS CORPORATION
Reel/Frame 062349/0298 →
Continuity (2)
Provisional Application 63246573 · Sep 21, 2021
Related Publication 20230116446A1 · Apr 13, 2023
References Cited (72)
US 7033590B1 · Scheiflinger et al. · 2006 [cited by applicant]
US 7112324B1 · Dorken et al. · 2006 [cited by applicant]
US 7235641B2 · Kufer · 2007 [cited by applicant]
US 10752929B2 · De Kruif · 2020 [cited by examiner]
US 20030133939A1 · Ledbetter et al. · 2003 [cited by applicant]
US 20050136049A1 · Ledbetter et al. · 2005 [cited by applicant]
US 20060135430A1 · Chan et al. · 2006 [cited by applicant]
US 20060246004A1 · Adams et al. · 2006 [cited by applicant]
US 20070059306A1 · Grossmaire et al. · 2007 [cited by applicant]
US 20080279850A1 · Brady et al. · 2008 [cited by applicant]
US 20090010921A1 · Umana et al. · 2009 [cited by applicant]
US 20100189722A1 · Heider · 2010 [cited by examiner]
US 20120219549A1 · Fertig et al. · 2012 [cited by applicant]
US 20120276119A1 · Decker et al. · 2012 [cited by applicant]
US 20140348745A1 · Larsen et al. · 2014 [cited by applicant]
US 20200095310A1 · Regula et al. · 2020 [cited by applicant]
US 20210214436A1 · Chang et al. · 2021 [cited by applicant]
US 20210246228A1 · Schlothauer et al. · 2021 [cited by applicant]
US 20210277150A1 · Von Kreudenstein · 2021 [cited by applicant]
US 20220411492A1 · Yang · 2022 [cited by examiner]
CA 3165045A1 · 2021 [cited by applicant]
CN 101815725A · 2010 [cited by applicant]
CN 102159243A · 2011 [cited by applicant]
CN 1852976B · 2012 [cited by applicant]
CN 103360494A · 2013 [cited by applicant]
CN 101827611B · 2014 [cited by applicant]
CN 103501815A · 2014 [cited by applicant]
CN 1902231B · 2015 [cited by applicant]
CN 112062855A · 2020 [cited by examiner]
EP 2586798A2 · 2013 [cited by applicant]
EP 2562187A1 · 2013 [cited by applicant]
EP 3489262A1 · 2019 [cited by examiner]
WO 2009126944A1 · 2009 [cited by applicant]
WO 2013033008A2 · 2013 [cited by applicant]
WO 2014081954A1 · 2014 [cited by applicant]
WO WO2017205014A1 · 2017 [cited by examiner]
WO WO2020180811A1 · 2020 [cited by examiner]
WO 2021026387A9 · 2021 [cited by applicant]
Merchant, A. Margaret, et al. “An efficient route to human bispecific lgG.” Nature biotechnology 16.7 (1998): 677-681. (Year: 1998). [cited by examiner]
Ha, Ji-Hee, Jung-Eun Kim, and Yong-Sung Kim. “Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins.” Frontiers in Immunology 7 (2016): 394. (Year: 2016). [cited by examiner]
Moore, Gregory L., et al. “A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.” Methods 154 (2019): 38-50. (Year: 2019). [cited by examiner]
Li, Yifeng, et al. “A roadmap for lgG-like bispecific antibody purification.” Approaches to the purification, analysis and characterization of antibody-based therapeutics. Elsevier, 2020. 167-179. (Year: 2020). [cited by examiner]
Muda et al. “Therapeutic assessment of SEED: a new engineered antibody platform designed to generate monoand pispecific antibodies,” Protein Engineering, Design & Selection, May 31, 2011 (May 31, 2011), vol. 24, No. 5, … [cited by applicant]
International Search Report and Written Opinion for PCT/US2022/076758 dated Jan. 23, 2023, 13 pages. [cited by applicant]
Krah et al., “Generation of human bispecific common lightchain antibodies by combining animalimmunization and yeast display”, Protein Engineering, Design & Selection, vol. 30, No. 4—pp. 291-301; Jan. 6, 2017. [cited by applicant]
Labrijn et al., “Bispecific antibodies: a mechanistic review of the pipeline”, Nature Reviews, Drug Discovery, Jun. 7, 2019. [cited by applicant]
Gunasekaran et al., “Enhancing Antibody Fc Heterodimer Formation throughElectrostatic Steering Effects”, The Journal of Biological Chemistry, vol. 285, No. 25, pp. 19637-19646, Jun. 18, 2010. [cited by applicant]
Suurs et al., “A review of bispecific antibodies and antibody constructs in oncology and clinical challenges”, Pharmacology & Therapeutics, Apr. 24, 2019. [cited by applicant]
Ridgway et al., Knobs-into-holes engineering of antibody CH3 Domains for heavy chain heterodimerization, Protein Engineering, vol. 9, pp. 617-621, 1996. [cited by applicant]
Liu et al., A Novel Antibody Engineering Strategy for MakingMonovalent Bispecific Heterodimeric IgG Antibodies byElectrostatic Steering Mechanism, Journal of Biological Chemistry, vol. 290, No. 12, Mar. 20, 2015. [cited by applicant]
Davis et al., SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies, Protein Engineer… [cited by applicant]
Kai et al., Switching constant domainsenhances agonist activitiesof antibodies to athrombopoietin receptor, Nature Biotechnology, vol. 26, No. 2, Feb. 2008. [cited by applicant]
Alduaij et al., “The future of anti-CD20 monoclonal antibodies: are we making progress?”, School of Cancer and Enabling Sciences, vol. 117, No. 11, Mar. 17, 2011. [cited by applicant]
Cragg, “CD20 antibodies: doing the time warp”, Bloodjournal.org, Sep. 2, 2015. [cited by applicant]
Vugmeyster et al., “Depletion of B Cells by a Humanized Anti-CD20Antibody PRO70769 inMacaca Fascicularis”, J Immunother vol. 28, No. 3, May/Jun. 2005. [cited by applicant]
Niederfellner et al., “Epitope characterization and crystal structure of GA101 provide insights into themolecular basis for type I/II distinction of CD20 antibodies”, Lymphoid Neoplasia, vol. 118, Jan. 12, 2015. [cited by applicant]
Beers et al., “Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I(rituximab-like) reagents in B-cell depletion regardless of complement activation”, Blood, vol. 112, No. 10, Nov. 15, 2008. [cited by applicant]
Illdge et al., “Obinutuzumab in hematologic malignancies: Lessons learned to date”, Cancer Treatment Reviews 41 (2015) 784-792. [cited by applicant]
Teelin et al., “The Biological Activity of Human CD20 Monoclonal Antibodies is Linked to Unique Epitopes on CD20”, The Journal of Immunology, Sep. 1, 2015. [cited by applicant]
Quinta's-Cardama, “Investigational Immunotherapeutics for B-Cell Malignancies”, Journal Ofclinicaloncology, vol. 28, No. 5, Feb. 10, 2010. [cited by applicant]
Letters to the Editor, “Action of novel CD37 antibodies on chronic lymphocytic leukemia cells”, Leukemia (2012) 26, 546-549; doi:10.1038/leu.2011.233; published online Sep. 2, 2011. [cited by applicant]
Zhao et al., “Targeting CD37-positive lymphoid malignancies with a novel engineered small modular Immunopharmaceutical”, Blood Journal, Oct. 31, 2015. [cited by applicant]
Heider et al., “A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies”, The American Society of Hermatology, 2011. [cited by applicant]
Deckert et al., “A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies”, Blood Journal, The American Society of Hermatology, 2013. [cited by applicant]
Berberichl “Cross-linking CD40 on B cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases” The EMBO Journal vol. 15 No. 1 pp. 92-101, 1996. [cited by applicant]
Robak, GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell ymphoid malignanices, Thomson Reuters, 2009. [cited by applicant]
Klein et al., “Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties”, mAbs 5:1, 22-33; Jan./Feb. 2013; Landes Bioscience. [cited by applicant]
Vaughan et al., “Activatory and Inhibitory FcReceptors AugmentRituximab-mediated Internalization of CD20 Independent ofSignaling via the Cytoplasmic Domain”, The Journal of Biological Chemistry vol. 290, No. 9, pp. 5424… [cited by applicant]
Small et al., Analysis of innate and acquired resistance to anti-CD20 antibodies in, malignant and nonmalignant B cells, Peer J., Nov. 21, 2012. [cited by applicant]
Mossner, “Increasing the efficacy of CD20 antibody therapy through the engineering of anew type II anti-CD20 antibody with enhanced direct and immune effectorcell-mediated B-cell cytotoxicity” Blood Journal, Jun. 3, 201… [cited by applicant]
Camilla De Nardis et al: “A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G 1”, Journal of Biological Chemistry, vol. 292, No.… [cited by applicant]
Partial Search Report for European Application No. Application No. 22873817.5, dated Sep. 7, 2025, 41 pages. [cited by applicant]